Cargando…
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma
The introduction of first-line combinations had improved the outcomes for metastatic renal cell carcinoma (mRCC) compared to sunitinib. However, some patients either have inherent resistance or develop resistance as a result of the treatment. Depending on the kind of therapy employed, many factors u...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571064/ https://www.ncbi.nlm.nih.gov/pubmed/37842234 http://dx.doi.org/10.20517/cdr.2023.33 |